Sunday 18 October 2026
Export NAUT’s income statement to Excel — free account
Nautilus Biotechnology, Inc.
NAUT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 8.33% and free cash flow fell 3.16%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.06
0.10
−4.63%
Follow NAUT
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
13.33 | 17.40 | 19.39 | 27.57 | 60.09 | 25.73 | — | — |
Net Debt/EBITDA |
1.67 | 1.67 | 2.37 | 3.02 | 7.28 | 5.85 | — | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.86 | 0.84 | 0.81 | 0.79 | 0.78 | 0.90 | — | — |
Capex/Depreciation |
(0.25) | (0.58) | (0.80) | (0.92) | (0.75) | (0.35) | — | — |
| (32.27%) | (29.86%) | (21.95%) | (17.07%) | (30.14%) | (9.36%) | — | — | |
| (27.20%) | (25.82%) | (19.42%) | (15.48%) | (20.81%) | (36.75%) | 0.00% | — | |
ROIC |
(77.98%) | (64.59%) | (51.77%) | (30.48%) | (176.84%) | 0.00% | — | — |
Return on Tangible Assets |
(58.15%) | (54.75%) | (37.02%) | (31.46%) | (14.55%) | (20.55%) | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(0.41) | (0.49) | (0.43) | (0.39) | (0.49) | (0.51) | — | — |
Cash per Share |
0.82 | 1.04 | 1.39 | 1.48 | 4.09 | 2.64 | — | — |
Shareholders Equity per Share |
1.24 | 1.66 | 2.12 | 2.53 | 4.30 | (1.02) | — | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Book value per Share |
1.24 | 1.66 | 2.12 | 2.53 | 4.30 | (1.02) | — | — |
Free Cash Flow |
(51.97) | (61.27) | (54.15) | (48.13) | (41.51) | (14.92) | — | — |
Working Capital |
98.01 | 125.19 | 167.72 | 180.42 | 343.41 | 74.64 | — | — |
Capital Expenditures |
(1.28) | (2.12) | (2.44) | (2.32) | (2.27) | (0.92) | — | — |
Net Current Asset Value |
71.82 | 98.81 | 136.63 | 152.08 | 314.35 | (37.07) | — | — |
| Other line items | ||||||||
Quick Ratio |
13.00 | 17.02 | 19.01 | 27.16 | 59.49 | 25.43 | — | — |
Depreciation/Fixed assets |
1.46 | 0.89 | 0.71 | 0.68 | 1.22 | 1.92 | — | — |
Cash ROIC |
(19.96%) | (18.09%) | (12.34%) | (9.64%) | (5.85%) | (31.72%) | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Operating CF per Share |
(0.40) | (0.47) | (0.41) | (0.37) | (0.46) | (0.48) | — | — |
Capex per Share |
(0.01) | (0.02) | (0.02) | (0.02) | (0.03) | (0.03) | — | — |
Average Payables |
0.97 | 1.31 | 1.46 | 1.50 | 1.10 | 1.10 | — | — |
Average Assets |
216.93 | 274.15 | 327.81 | 374.25 | 241.73 | 42.51 | 0.00 | — |
Average Common Equity |
182.85 | 237.04 | 290.14 | 339.25 | 166.93 | 166.93 | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Columns are period end dates